ClinicalTrials.gg
CompletedNCT00665223MermaiHDUpdated Aug 29, 2023Results posted

A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease

A Phase 3 interventional study of ACR16 and Placebo in Huntington's Disease, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 31 sites in 8 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2023-08-29.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
437
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Huntington Disease with a site in United Kingdom — 10 open to participants now, 15 under way, 3 of them phase 3. Huntington Disease · United Kingdom.

Enrollment
3rd of 38
437 · median 92
Started
2008
the only one that year
Phase 3
7 of 51
2 open now
Registered
1st of 51
by date
Lead sponsor
2 of 51
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 51 studies in Huntington Disease with a site in United Kingdom, this one is the 3rd largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2008, is one of 7 in phase 3, and was the 1st registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

10 of the 51 studies in Huntington Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Huntington Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's disease.

Read the detailed description

The primary objective in the present study is to confirm whether ACR16 is efficacious in improving voluntary motor function in Huntington's disease based on the Unified Huntington"s Disease Rating Scale (UHDRS) subscale. These symptoms seem to be most important for the functional disability associated with the disorder. To achieve this, participants are randomized to ACR16 45 mg once daily, ACR16 45 mg twice daily, or placebo treatment in equal proportions in a parallel design for a treatment duration of 26 weeks.

03

Conditions studied

  • Huntington's Disease

Browse trials for

Keywords

  • Huntington's Disease
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written prior to any study related procedure.
  • Huntington's disease diagnosed with the aid of clinical features and a positive family history and/or the presence of ≥ 36 CAG repeats in the Huntington gene.
  • Male or female age ≥ 30 years.
  • Willing and able to take oral medication and able to comply with the study specific procedures.
  • Ambulatory, being able to travel to the assessment centre, and judged by the Investigator as likely to be able to continue to travel for the duration of the study.
  • Availability of a caregiver or family member to accompany the participant.
  • A sum of ≥ 10 points on the mMS at the screening visit.
  • For participants taking allowed antipsychotic medication, the dosing of medication must have been kept constant for at least 6 weeks before randomization. The allowed antipsychotic medication is Amisulpride, Haloperidol, Olanzapine, Risperidone, Sulpiride, or Tiapride.
  • For participants taking allowed antidepressant or other psychotropic medication, the dosing of medication must have been kept constant for at least 6 weeks before randomization.
  • Willing to provide a blood sample for CAG analysis (where CAG result is not already available).
  • In France only, the participant must be affiliated to a social security system or be a beneficiary of such a system.

Exclusion criteria

Exclusion Criteria:

  • Unable to give written .
  • Treatment with any non-allowed antipsychotic medication within 12 weeks of randomization. The non-allowed antipsychotic medication is any medication other than Amisulpride, Haloperidol, Olanzapine, Risperidone, Sulpiride, or Tiapride.
  • Treatment with the antidepressants Fluoxetine or Paroxetine within 6 weeks of randomization.
  • Use of Tetrabenazine within 12 weeks of randomization, or at any time during the study period.
  • Treatment with any product within 4 weeks of randomization.
  • Use of tricyclic antidepressants, class I antiarrhythmics, and strong CYP2D6 inhibitors such as Ajmalicine, Chinidin/Quinidine and Ritonavir, within 6 weeks of randomization.
  • Participants previously included into this study.
  • A prolonged at screen (defined as a QTc interval of > 450 milliseconds [msec] for males or > 470 msec for females), or other heart conditions.
  • \<40 milliliters (mL)/minute (min) as measured at the screening visit.
  • Any clinically significant, abnormal, baseline laboratory result which in the opinion of the Investigator, affects the participants' suitability for the study or puts the participant at risk if he/she enters the study.
  • Clinically significant hepatic or renal impairment.
  • Participants with a history of epilepsy or a history of seizure(s) of unknown cause.
  • Severe intercurrent illness, which, in the opinion of the Investigator, may put the participant at risk when participating in the trial or may influence the results of the trial or affect the participants' ability to take part in the trial.
  • Alcohol and/or drug abuse as defined by Diagnostic and Statistical Manual - Fourth Edition - Text Revision (DSM IV-TR) criteria for substance abuse - this includes the illicit use of cannabis within the last 12 months.
  • Participants with suicidal ideation, defined as a positive score on criteria for major depressive episode, item A9 on the criteria for a Major Depressive Episode.
  • Females who are pregnant or lactating.
  • Females who are of child bearing potential and not taking adequate precautions are excluded from the trial. Females of child bearing potential taking acceptable contraceptive precautions can be included.
  • Known allergy to any ingredients of the trial medication or placebo.
  • Any previous participation in a clinical study with ACR16.
  • Participants currently receiving deep brain stimulation.
  • Participants with a history of surgical procedures aiming to improve the symptoms of Huntington's disease, such as neural transplantations, lesions of the central nervous system, infusions of neurotrophic agents or previous attempts of deep brain stimulation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
437 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive a placebo capsule matching to ACR16 once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 26), placebo capsule will be taken twice daily as 2 separate doses.

    Drug: Placebo

  • Experimental
    ACR16 45 mg

    Participants will receive ACR16 45 milligrams (mg) capsule orally once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 26), one ACR16 45 mg capsule and one placebo capsule will be taken as 2 separate doses.

    Drug: ACR16 · Drug: Placebo

  • Experimental
    ACR16 90 mg

    Participants will receive ACR16 45 mg capsule once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 26), ACR16 45 mg capsule will be taken twice daily as 2 separate doses (total dose: 90 mg)

    Drug: ACR16

Interventions

  • DrugACR16

    Capsules will be swallowed whole with water.

    Also known as: Pridopidine

  • DrugPlacebo

    Capsules will be swallowed whole with water.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the Unified Huntington's Disease Rating Scale [UHDRS] Motor Assessments) at Week 26

    The mMS is a subscale of the UHDRS total motor score and comprises 13 responses from the 10 items, 4-10 and 13-15, from the UHDRS motor assessment. The items for mMS include dysarthria, tongue protrusion, finger taps (right and left), pronate/supinate hands (right and left), luria - first-hand-palm sequencing, arms rigidity (right and left), body bradykinesia, gait, tandem walking, and retropulsion pull test. Each of these items are rated on a scale of 0 (normal) to 4 (marked impairment). Total score ranges from 0 to 52, with higher scores indicating more severe motor impairment.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. The UHDRS Functional Assessment at Week 26

    The UHDRS Functional Assessment considers 25 items associated with functional problems. The participant scores 1 point for every item to which they respond positively (zero points for negative responses). Total score ranges from 0 (worst) to 25 (best). Higher scores indicate better functional ability.

    Time frame: Week 26

  2. Number of Participants With Clinical Global Impression - Improvement (CGI-I) Score

    Global improvement is rated by the investigator on a 7-point scale as: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; and 7 = Very much worse.

    Time frame: Week 26

  3. Change From Baseline in Stroop Word Reading Test at Week 26

    The Stroop test measures the ability to concentrate and ward off distractions. The test consists of three items: (i) colour naming; (ii) word reading; (iii) interference. The word reading test requires participants to read colour words written in black and each response is scored as the number of correct answers made in 45 seconds. Higher scores indicate less severe disease, and an increase in score represents an improvement.

    Time frame: Baseline, Week 26

  4. Change From Baseline in Total UHDRS Behavioral Assessment Score at Week 26

    The total behavioral assessment score is the sum of the 11 products (depressed mood, apathy, low self-esteem/guilt, compulsive behavior, anxiety, irritable behavior, perseverative/obsessive thinking, disruptive/aggressive behavior, suicidal thoughts, delusions, and hallucinations) of frequency and severity symptom scores and excluded the 3 yes/no questions relating to confusion, dementia, and depression. Frequency is rated on a scale of 0 (never or almost never) to 4 (very frequently, most of the time). Severity is rated on a scale of 0 (no evidence) to 4 (severe). Total behavior score ranges from 0 (no impairment) to 88 (severe impairment), with higher scores indicating greater behavioral impairments.

    Time frame: Baseline, Week 26

  5. Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score at Week 26

    HADS is a self-administered instrument reliable for detecting states of depression and anxiety. It includes 2 subscales: Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale is comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score ranges from 0 to 21 for each subscale where higher scores indicate greater severity of anxiety and depression symptoms. The total HADS score was a composite score summed of all 14 items for a total range of 0 to 42. Lower change from baseline scores indicate improvement.

    Time frame: Baseline, Week 26

  6. Randomized Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any change from the participant's baseline (pre-treatment) condition, other than improvement, that did not necessarily have causal relationship with the study drug. TEAEs were defined as AEs that began after ACR16/placebo administration through week 26 or up to week 30 for participants not continuing in the open-label period. AEs included both serious adverse events (SAEs) and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.

    Time frame: Baseline up to Week 30

  7. Open-label Phase: Number of Participants With TEAEs

    An AE was defined as any change from the participant's baseline (pre-treatment) condition, other than improvement, that did not necessarily have causal relationship with the study drug. TEAEs were defined as adverse events that began after ACR16/placebo administration through Week 56. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.

    Time frame: Week 26 up to Week 56

07

Results

Posted Aug 29, 2023

Participant flow

Randomized Phase (26 Weeks)
Participant flow — Randomized Phase (26 Weeks)
MilestonePlacebo/ACR16 90 mgACR16 45 mg/90 mgACR16 90 mg/90 mg
Started144148145
Received at least 1 dose of study drug144148145
Completed126136124
Not completed181221
Withdrew: Adverse event13915
Withdrew: Death001
Withdrew: Withdrawal by subject523
Withdrew: Protocol violation011
Withdrew: Other than specified001
Open-Label Period (26 Weeks)
Participant flow — Open-Label Period (26 Weeks)
MilestonePlacebo/ACR16 90 mgACR16 45 mg/90 mgACR16 90 mg/90 mg
Started113125115
Completed97108100
Not completed161715
Withdrew: Adverse event8117
Withdrew: Death010
Withdrew: Lost to follow-up312
Withdrew: Withdrawal by subject534
Withdrew: Protocol violation010
Withdrew: Other than specified002

Outcome measures

PrimaryChange From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the Unified Huntington's Disease Rating Scale [UHDRS] Motor Assessments) at Week 26

The mMS is a subscale of the UHDRS total motor score and comprises 13 responses from the 10 items, 4-10 and 13-15, from the UHDRS motor assessment. The items for mMS include dysarthria, tongue protrusion, finger taps (right and left), pronate/supinate hands (right and left), luria - first-hand-palm sequencing, arms rigidity (right and left), body bradykinesia, gait, tandem walking, and retropulsion pull test. Each of these items are rated on a scale of 0 (normal) to 4 (marked impairment). Total score ranges from 0 to 52, with higher scores indicating more severe motor impairment.

Time frame:
Baseline, Week 26
Reported as:
Mean · units on a scale
Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the Unified Huntington's Disease Rating Scale [UHDRS] Motor Assessments) at Week 26
units on a scalePlacebo/ACR16 90 mgACR16 45 mg/90 mgACR16 90 mg/90 mg
Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the Unified Huntington's Disease Rating Scale [UHDRS] Motor Assessments) at Week 260.27 ± 4.43-0.23 ± 4.12-0.94 ± 3.87
Statistical analysis
  • Placebo/ACR16 90 mg vs ACR16 45 mg/90 mg · ANCOVA · p = 0.456 · Mean difference (final values): -0.36 · 97.5% CI -1.44 to 0.72
  • Placebo/ACR16 90 mg vs ACR16 90 mg/90 mg · ANCOVA · p = 0.042 · Mean difference (final values): -0.99 · 97.5% CI -2.08 to 0.10
SecondaryThe UHDRS Functional Assessment at Week 26

The UHDRS Functional Assessment considers 25 items associated with functional problems. The participant scores 1 point for every item to which they respond positively (zero points for negative responses). Total score ranges from 0 (worst) to 25 (best). Higher scores indicate better functional ability.

Time frame:
Week 26
Reported as:
Mean · Units on a Scale
The UHDRS Functional Assessment at Week 26
Units on a ScalePlacebo/ACR16 90 mgACR16 45 mg/90 mgACR16 90 mg/90 mg
The UHDRS Functional Assessment at Week 2616.81 ± 6.2017.50 ± 5.7317.48 ± 5.43
SecondaryNumber of Participants With Clinical Global Impression - Improvement (CGI-I) Score

Global improvement is rated by the investigator on a 7-point scale as: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; and 7 = Very much worse.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Participants With Clinical Global Impression - Improvement (CGI-I) Score
ParticipantsPlacebo/ACR16 90 mgACR16 45 mg/90 mgACR16 90 mg/90 mg
Very much improved111
Much improved887
Minimally improved303233
No change555950
Minimally worse383746
Much worse792
Very much worse000
Missing001
SecondaryChange From Baseline in Stroop Word Reading Test at Week 26

The Stroop test measures the ability to concentrate and ward off distractions. The test consists of three items: (i) colour naming; (ii) word reading; (iii) interference. The word reading test requires participants to read colour words written in black and each response is scored as the number of correct answers made in 45 seconds. Higher scores indicate less severe disease, and an increase in score represents an improvement.

Time frame:
Baseline, Week 26
Reported as:
Mean · correct responses
Change From Baseline in Stroop Word Reading Test at Week 26
correct responsesPlacebo/ACR16 90 mgACR16 45 mg/90 mgACR16 90 mg/90 mg
Change From Baseline in Stroop Word Reading Test at Week 26-1.3 ± 11.9-1.1 ± 10.3-0.8 ± 11.7
SecondaryChange From Baseline in Total UHDRS Behavioral Assessment Score at Week 26

The total behavioral assessment score is the sum of the 11 products (depressed mood, apathy, low self-esteem/guilt, compulsive behavior, anxiety, irritable behavior, perseverative/obsessive thinking, disruptive/aggressive behavior, suicidal thoughts, delusions, and hallucinations) of frequency and severity symptom scores and excluded the 3 yes/no questions relating to confusion, dementia, and depression. Frequency is rated on a scale of 0 (never or almost never) to 4 (very frequently, most of the time). Severity is rated on a scale of 0 (no evidence) to 4 (severe). Total behavior score ranges from 0 (no impairment) to 88 (severe impairment), with higher scores indicating greater behavioral impairments.

Time frame:
Baseline, Week 26
Reported as:
Mean · units on a scale
Change From Baseline in Total UHDRS Behavioral Assessment Score at Week 26
units on a scalePlacebo/ACR16 90 mgACR16 45 mg/90 mgACR16 90 mg/90 mg
Change From Baseline in Total UHDRS Behavioral Assessment Score at Week 260.12 ± 13.51-0.41 ± 16.78-2.22 ± 10.84
SecondaryChange From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score at Week 26

HADS is a self-administered instrument reliable for detecting states of depression and anxiety. It includes 2 subscales: Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale is comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score ranges from 0 to 21 for each subscale where higher scores indicate greater severity of anxiety and depression symptoms. The total HADS score was a composite score summed of all 14 items for a total range of 0 to 42. Lower change from baseline scores indicate improvement.

Time frame:
Baseline, Week 26
Reported as:
Mean · units on a scale
Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score at Week 26
units on a scalePlacebo/ACR16 90 mgACR16 45 mg/90 mgACR16 90 mg/90 mg
Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score at Week 26-0.10 ± 6.04-0.73 ± 6.780.13 ± 6.00
SecondaryRandomized Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any change from the participant's baseline (pre-treatment) condition, other than improvement, that did not necessarily have causal relationship with the study drug. TEAEs were defined as AEs that began after ACR16/placebo administration through week 26 or up to week 30 for participants not continuing in the open-label period. AEs included both serious adverse events (SAEs) and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.

Time frame:
Baseline up to Week 30
Reported as:
Count of participants · Participants
Randomized Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsRandomized Phase: PlaceboRandomized Phase: ACR16 45 mgRandomized Phase: ACR16 90 mg
Randomized Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)929199
SecondaryOpen-label Phase: Number of Participants With TEAEs

An AE was defined as any change from the participant's baseline (pre-treatment) condition, other than improvement, that did not necessarily have causal relationship with the study drug. TEAEs were defined as adverse events that began after ACR16/placebo administration through Week 56. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.

Time frame:
Week 26 up to Week 56
Reported as:
Count of participants · Participants
Open-label Phase: Number of Participants With TEAEs
ParticipantsOpen-label Phase: Placebo/ACR16 90 mgOpen-label Phase: ACR16 45 mg/90 mgOpen-label Phase: ACR16 90 mg/90 mg
Open-label Phase: Number of Participants With TEAEs9010195

Adverse events

Collected over Baseline up to Week 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomized Phase: Placebo—11/144 (7.6%)54/144 (37.5%)
Randomized Phase: ACR16 45 mg—10/148 (6.8%)49/148 (33.1%)
Randomized Phase: ACR16 90 mg—9/145 (6.2%)56/145 (38.6%)
Open Label Phase: Placebo—6/113 (5.3%)38/113 (33.6%)
Open Label Phase: ACR 16—15/240 (6.3%)88/240 (36.7%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventRandomized Phase: PlaceboRandomized Phase: ACR16 45 mgRandomized Phase: ACR16 90 mgOpen Label Phase: PlaceboOpen Label Phase: ACR 16
SUICIDE ATTEMPTPsychiatric disorders1/1440/1482/1450/1130/240
DISEASE PROGRESSIONGeneral disorders1/1440/1480/1451/1130/240
AGITATIONPsychiatric disorders0/1440/1481/1451/1132/240
GASTROENTERITISInfections and infestations0/1440/1480/1451/1130/240
HEAD INJURYInjury, poisoning and procedural complications0/1440/1480/1451/1130/240
BREAST CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1440/1480/1451/1130/240
MAJOR DEPRESSIONPsychiatric disorders0/1440/1480/1451/1131/240
ANAL SPASMGastrointestinal disorders1/1440/1480/1450/1130/240
CONSTIPATIONGastrointestinal disorders1/1440/1480/1450/1130/240
ALCOHOL POISONINGInjury, poisoning and procedural complications1/1440/1480/1450/1130/240
Most frequent other events
Showing 10 of 11
Most frequent other events
EventRandomized Phase: PlaceboRandomized Phase: ACR16 45 mgRandomized Phase: ACR16 90 mgOpen Label Phase: PlaceboOpen Label Phase: ACR 16
FALLInjury, poisoning and procedural complications12/1447/14815/14514/11324/240
HUNTINGTON'S CHOREACongenital, familial and genetic disorders9/1447/14810/1457/11329/240
NASOPHARYNGITISInfections and infestations6/1449/14810/1455/1139/240
DIARRHOEAGastrointestinal disorders7/14410/1489/1453/1138/240
DIZZINESSNervous system disorders6/14410/1488/1454/1136/240
NAUSEAGastrointestinal disorders9/1449/1485/1452/1135/240
FATIGUEGeneral disorders9/1447/1484/1454/1136/240
INSOMNIAPsychiatric disorders5/1445/1489/1453/1138/240
DEPRESSIONPsychiatric disorders8/1446/1486/1454/11311/240
HEADACHENervous system disorders4/1444/1488/1454/1134/240

Baseline characteristics

Full analysis set included all randomized participants who received at least 1 dose of study drug and had undergone at least 1 clinical assessment post randomization.

Age, Continuous
Age, Continuous(years)Placebo/ACR16 90 mgACR16 45 mg/90 mgACR16 90 mg/90 mgTotal
Mean49.1 ± 9.651.0 ± 10.751.8 ± 11.150.6 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/ACR16 90 mgACR16 45 mg/90 mgACR16 90 mg/90 mgTotal
Female768264222
Male686681215
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo/ACR16 90 mgACR16 45 mg/90 mgACR16 90 mg/90 mgTotal
Race — Asian0202
Race — Other0101
Race — Caucasian144145145434
Unified Huntington's Disease Rating Scale (UHDRS) Modified Motor Score (mMS)
Unified Huntington's Disease Rating Scale (UHDRS) Modified Motor Score (mMS)(units on a scale)Placebo/ACR16 90 mgACR16 45 mg/90 mgACR16 90 mg/90 mgTotal
Mean19.43 ± 8.2818.38 ± 6.7618.57 ± 6.9018.79 ± 7.34
08

Study locations

31 sites
  • LKH -Univ. Klinikum Graz, Universitaetsklinik fur Psychiatrie Graz
    Graz, Styria 8036, Austria
  • Innsbruck Medical University, Anichstraße 35
    Innsbruck, Tyrol A-6020, Austria
  • University Hospital Gasthuisberg
    Leuven, Flemish Brabant 3000, Belgium
  • Hôpital Purpan, Place Docteur-Baylac, Bâtiment F
    Toulouse Cedex 9, Midi-Pyrénées Region 31059, France
  • CHU Roger Salengro
    Lille Cedex, Nord-Pas De Calais 59037, France
  • Hôpital Nord, CHU d'Amiens, Service de Neurologie
    Amiens Cedex 1, Picardie 80054, France
  • CHU La Timone, 264 Rue Saint Pierre
    Marseille Cedex 05, Provence-Alpes-Cote d'Azur 13385, France
  • Universitätsklinik Ulm, Neurologie/ Oberer Eselberg 45/1
    Ulm, Baden-Württemberg 89081, Germany
  • Klinikum rechts der Isar der Technischen Universität München, Neurologische Klinik und Poliklinik, Ismaninger Str. 22
    München, Bavaria 81675, Germany
  • Isar Amper Klinikum gemeinnützige GmbH, Klinik Taufkirchen (Vils), Bräuhausstr.5
    Taufkirchen (Vils), Bavaria 84416, Germany
  • St. Josef Hospital, Ruhr University Bochum, Gudrunstraße 56
    Bochum, North Rhine-Westphalia 44791, Germany
  • Westfaelische Wilhelms-Universitaet Muenster, Klinik fur Neurologie
    Muenster, North Rhine-Westphalia 48149, Germany
  • Universitat Dresden, Klinikum Carl Gustav Carus, Fetscherstr. 74
    Dresden, Saxony 01307, Germany
  • Klinik für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Schumannstrasse 20/21
    Berlin, 10117, Germany
  • Fondazione IRCCS Istituto Nazionale Neurologico "Carlos Besta", Department of Movement Disorders, 11 via Celoria
    Milano, Lombardy 20133, Italy
  • IRCCS Neuromed, Localita Camarelle
    Pozzilli, Molise 86077, Italy
  • University Hospital of Coimbra, Av. Rissaya Barreto
    Coimbra, Baixo Mondego 3000-075, Portugal
  • Centro de Estudos Egas Moniz, Faculdade de Medicina de Lisboa, Av. Prof. Egas Moniz
    Lisboa, 1649-028, Portugal
  • Hospital Mútua de Terrassa, C/ Castell
    Terrassa, Catalonia 08225, Spain
  • Hospital Clinic of Barcelona, Calle Villarroel, 170
    Barcelona, 08036, Spain
  • Hospital Ramon y Cajal, Carretera Colemenar km 9.100
    Madrid, 28034, Spain
  • Hospital Universitario La Fe, Avda. Campanar 21,
    Valencia, 46009, Spain
  • R&D Headquarters, Barberry Centre, 25 Vincent Drive
    Birmingham, England/West Midlands B15 2SG, United Kingdom
  • Department of Clinical Genetics, St Mary's Hospital, Hathersage Road
    Manchester, North West England M13 9WL, United Kingdom
  • First Floor Argyll House, Fosterhill, Cornhill Road
    Aberdeen, Scotland AB25 2ZR, United Kingdom
  • SE Scotland Genetic Service, Western General Hospital, Crewe Road
    Edinburgh, Scotland EH4 2XU, United Kingdom
  • Churchill Hospital, Old Road, Headington
    Oxford, South East England OX3 7LJ, United Kingdom
  • Academic Neurology Unit, E Floor Medical School Beech Hill Road
    Sheffield, South Yorkshire S10 2RX, United Kingdom
  • Institute of Human Genetics, Centre for Life, Central Parkway
    Newcastle on Tyne, Tyne And Wear NE1 3BZ, United Kingdom
  • Cardiff University School of Medicine, Department of Neurology & Medical Genetics, Heath Park
    Cardiff, Wales CF14 4XN, United Kingdom
  • Cambridge Centre for Brain repair, Cambridge University
    Cambridge, CB2 2PY, United Kingdom
09

References and documents

Publications

  • de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt A, Tedroff J; MermaiHD study investigators. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011 Dec;10(12):1049-57. doi: 10.1016/S1474-4422(11)70233-2. Epub 2011 Nov 7. PubMed 22071279 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2008 to primary completion in Jun 2010, 25 months.

Results were first posted in Aug 2023, 13 years 2 months after primary completion. A results delay was requested in Feb 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2008
First posted
Apr 23, 2008
StartActual
Apr 24, 2008
Primary completionActual
Jun 14, 2010
CompletionActual
Jun 14, 2010
Results delay requested
Feb 19, 2013
Results first posted
Aug 29, 2023
Last update
Aug 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00665223
Responsible party
Sponsor
First posted
Apr 23, 2008
Start date
Apr 24, 2008
Primary completion
Jun 14, 2010
Completion
Jun 14, 2010
Results posted
Aug 29, 2023
Last update
Aug 29, 2023

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pridopidine

Start the discussion